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The UK Food Standards Agency convened a group of expert scientists to review current
research investigating whether n-3 polyunsaturated fatty acids (PUFA) from plant oils (a-lino-
lenic acid; ALA) were as beneficial to cardiovascular health as the n-3 PUFA from the marine
oils, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The workshop also aimed
to establish priorities for future research. Dietary intake of ALA has been associated with a
beneficial effect on CHD; however, the results from studies investigating the effects of ALA
supplementation on CHD risk factors have proved equivocal. The studies presented as part
of the present workshop suggested little, if any, benefit of ALA, relative to linoleic acid, on
risk factors for cardiovascular disease; the effects observed with fish-oil supplementation
were not replicated by ALA supplementation. There is a need, therefore, to first prove the effi-
cacy of ALA supplementation on cardiovascular disease, before further investigating effects on
cardiovascular risk factors. The workshop considered that a beneficial effect of ALA on the sec-
ondary prevention of CHD still needed to be established, and there was no reason to look
further at existing CHD risk factors in relation to ALA supplementation. The workshop also
highlighted the possibility of feeding livestock ALA-rich oils to provide a means of increasing
the dietary intake in human consumers of EPA and DHA.
a-Linolenic acid: Fish oils: Cardiovascular disease: Nutrition research
The Food Standards Agency (FSA) convened a workshop
on 18 March 2002, to examine the role of a-linolenic
acid (ALA) in relation to cardiovascular disease. The
results from recently completed studies were presented,
both FSA- and non-FSA-funded, and the workshop was
chaired by Professor Martijn Katan, Wageningen Univer-
sity, The Netherlands. The aim of the workshop was to
determine where this work has taken us and where further
work should be concentrated, as well as acting as a vehicle for
dissemination. The research recommendations emanating
from the workshop discussions will feed into the future direc-
tion of the UK FSA-funded nutrition research, and may also
be of value in guiding other funders internationally.
Background
The long chain n-3 polyunsaturated fatty acids (PUFA),
eicosapentanoic acid (EPA; 20 : 5n-3) and docosahexaenoic
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acid (DHA; 22 : 6n-3), have been shown to reduce the re-
occurrence of CHD (GISSI-Prevenzione Investigators,
1999). EPA and DHA also have a variety of beneficial
effects on risk factors for CHD. Oily fish is the richest diet-
ary source of EPA and DHA, but fish consumption is low
in habitual UK diets (Department of the Environment,
Food and Rural Affairs, 2001). An alternative source of
n-3 PUFA is the more abundant ALA (18 : 3n-3), which
can be elongated and desaturated to its long-chain deriva-
tives EPA and DHA; however, in man the extent and regu-
lation of this conversion is unclear. The question arises,
therefore, whether plant oils rich in ALA (for example, lin-
seed, rapeseed and nut oils) could reproduce the beneficial
effects of fish consumption on risk for cardiovascular dis-
ease, via conversion of ALA to its long-chain derivatives.
The Lyon Diet Heart Study (de Lorgeril et al. 1994,
1999) suggested that dietary ALA may have a remarkably
beneficial effect on the secondary prevention of CHD;
however, compared with the control diet, the experimental
diet also had a higher content of fruit and vegetables,
legumes, fibre-rich cereals, monounsaturated fatty acids,
less linoleic acid (LA; 18 : 2n-6) and less saturated fatty
acids, making it impossible to dissect out the role of indi-
vidual food components. Several prospective epidemiolo-
gical studies have reported a protective effect of ALA-
rich foods against CHD (Dolecek, 1992; Ascherio et al.
1996; Hu et al. 1999), although a more recent study of
elderly men (Oomen et al. 2001) found no association
between ALA intake and CHD.
The results from studies investigating the effects of ALA
supplementation on CHD risk factors have been equivocal.
ALA has been shown to be equivalent to LA and n-6-rich
oils for lipid and lipoprotein effects (Harris, 1997; Pang
et al. 1998) and, unlike fish-oil supplementation, results
in no effect on plasma triacylglycerol (TAG) levels
(Pang et al. 1998). The overall results from studies inves-
tigating any effect of ALA on haemostasis have proved
inconclusive (Knapp, 1997; Allman-Farinelli et al. 1999),
whereas fish-oil supplementation can lead to positive
effects on haemostasis (Mutanen & Freese, 2001). Arterial
endothelial function, a non-invasive marker of arterial
health, can be improved by fish-oil supplementation
(Nestel, 2000), and one study has reported a beneficial
effect of a high intake of ALA (20 g/d) on endothelial func-
tion in obese subjects; however, insulin sensitivity and
HDL-cholesterol diminished concomitantly (Nestel et al.
1997). Inflammation is a characteristic of many diseases,
including CHD. Fish-oil supplementation has been shown
to exhibit inhibitory effects on most tests of immune func-
tion and on inflammatory markers in human subjects
(Calder, 2001). There are only a few studies of the
immune and inflammatory effects of ALA in human sub-
jects. These show that supplementation with high intakes
of ALA (14 and 18 g/d) can partly inhibit lymphocyte pro-
liferation and the production of inflammatory cytokines
(Kelley et al. 1991; Caughey et al. 1996). Studies supple-
menting with lower amounts of ALA (2 or 4 g/d) reveal
limited impact (Healy et al. 2000; Thies et al. 2001a,b,c).
The studies presented as part of the present workshop
investigate the importance of ALA as a source of long
chain n-3 PUFA and its influence on risk factors for
CHD. These studies further the understanding of the effects
of ALA intake on haemostasis, endothelial function,
immune function, lipoprotein metabolism and its conver-
sion to long-chain derivatives.
The effects of plant- and marine-derived n-3
polyunsaturated fatty acids on coronary heart disease
risk factors in moderately hyperlipidaemic subjects
Dr Yvonne Finnegan presented the findings from a four-
centre Department for Environment, Food and Rural
Affairs–Biotechnology and Biological Sciences Research
Council-LINK (BBSRC-LINK) collaborative study co-
sponsored by Unilever and Hoffmann-la Roche and coordi-
nated at the University of Reading. The aim was to evalu-
ate the relative effects of dietary EPA plus DHA compared
with estimated biologically equivalent amounts of dietary
ALA on a range of risk factors for CHD. Following a 4-
week run-in period during which all subjects consumed a
typical n-6- PUFA rich margarine (control), 150 moder-
ately hyperlipidaemic men and women (aged 25–72
years) were randomised into one of five diets enriched in
either EPA+DHA (to a total daily intake of 0·8 g, n-6:n-3
ratio 9·6; or 1·7 g/d, n-6:n-3 ratio 6·5) or to biologically
equivalent amounts of ALA (to a total daily intake of
4·5 g, n-6:n-3 ratio 3·3; or 9·5 g/d, n-6:n-3 ratio 1·3) or to
control (no additional n-3 PUFA, n-6:n-3 ratio 10·5) for a
period of 6 months. The n-3 PUFA were incorporated in
the form of a 25 g portion of fat spread to replace the sub-
ject’s normal margarine or spread and three oil capsules.
The main findings from the study were as follows.
There was no significant effect of any of the n-3 inter-
ventions compared with the control on fasting serum
lipids (total, LDL- and HDL-cholesterol, TAG, non-esteri-
fied fatty acids), glucose or insulin or on the postprandial
TAG or glucose response following 6 months dietary inter-
vention. There was a trend for total and LDL-cholesterol
levels to be increased following the 1·7 g EPA+DHA/d
intervention, which was shown to be significant for total
cholesterol in females on EPA+DHA (þ17·4 (SD 3·9) %)
compared with the control females (þ4·0 (SD 2·5);
P,0·01).
Retrospective genotyping for apolipoprotein (apo) E
polymorphisms of subjects was carried out since previous
work in our group had shown subjects with an apo E4
genotype to be more responsive to the cholesterol-raising
effects of EPA and DHA (Minihane et al. 2000). In the pre-
sent study, a trend towards an increase in LDL-C in the apo
E4 subjects was evident with a 7·1 % decrease, 10·3 %
increase and 19·9 % increase in LDL-C in the apo E2, E3
and E4 groups respectively following the 1·7 g
EPA+DHA/d diet. However the small number of subjects
precludes definitive conclusions from this retrospective
analysis. An important question in this study was whether
ALA (at biologically equivalent levels) can mimic the
TAG-lowering effects of EPA+DHA. The findings suggest
no TAG-lowering effects of ALA and indicate the reverse
may be true since the mean change in fasting TAG follow-
ing an intake of 9·5 g ALA/d was þ10·9 % compared with
a decrease (27·7 %) in the EPA+DHA (1·7 g/d) group
(P,0·05).
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There was no significant effect of any of the n-3 inter-
ventions on systolic or diastolic blood pressure, on markers
of the blood coagulation (factor VIIc, factor VIIag, factor
VIIa, factor XIIa) or fibrinolytic (tissue plasminogen acti-
vator, plasminogen activator inhibitor) systems, or on mar-
kers of innate or acquired immune function compared with
control. An additional in vivo functional measure of
immune function (delayed hypersensitivity reaction) also
showed no effect of any of the n-3 interventions.
There was an increase in the susceptibility of ex vivo
LDL to oxidation following an intake of 1·7 g
EPA+DHA/d. Dietary ALA did not affect the susceptibility
of ex vivo LDL to oxidation. There was no effect of any of
the n-3 interventions on markers of antioxidant status
(plasma a-tocopherol, ferric-reducing ability of plasma)
measured in this study.
As expected both the EPA+DHA diets led to increases in
the proportion of EPA and DHA in plasma phospholipids
(PL) (P,0·05). Both ALA diets also led to significant
enrichment of plasma PL with ALA and EPA (P,0·05).
However, there was no change in the proportion of DHA
in the plasma PL despite the long-term supplementation
with ALA. The change in the proportion of plasma PL
EPA following the ALA diets was comparable to that
observed following the 1·7 g EPA+DHA/d diet suggesting
that the ratio of 7:1 we had used in estimating biologically
equivalent levels of dietary ALA and EPA+DHA was
approximately true. There was no incorporation of ALA
in platelet or mononuclear cell PL, although the proportion
of EPA was significantly increased following the higher
ALA (9·5 g/d) diet (P,0·05). However, consistent with
plasma PL, no significant changes in the proportion of
DHA in cell membrane PL were observed following
ALA supplementation.
In conclusion: (i) in middle-aged male and females,
increasing ALA in the diet increases tissue and circulating
EPA but not DHA levels; (ii) at feasible dietary levels (5–
10 g/d), ALA does not appear to mimic the reported effects
of the long-chain n-3 PUFA on blood lipids, haemostatic
factors or immune and inflammatory function; (iii) apart
from modest reductions in plasma TAG, previously
reported beneficial effects of EPA+DHA on blood lipids,
haemostatic and immune and inflammatory function were
not observed in the present study and may reflect the
lower levels of EPA and DHA used; (iv) potentially
adverse effects of EPA and DHA on total and LDL-choles-
terol may be modulated by gender and genotype.
The effects of altered meal and dietary n-3
polyunsaturated fatty acid intakes upon conversion of
a-linolenic acid to longer-chain fatty acids (in men)
Dr Steve Wootton presented results from studies designed
to characterise ALA conversion in men using stable-iso-
tope technology either following a test meal with differing
n-3 fatty acid content (FSA-funded) or after increasing
dietary consumption of ALA or EPA and DHA (as part
of the BBSRC-LINK study).
The first phase of studies investigated the acute effect of
meal n-3 fatty acid content upon ALA conversion. Six men
consumed one of three test meals on each of three
occasions: control (1 g ALA, n-3:n-6 ratio 0·15); high
ALA (6·3 g, n-3:n-6 ratio 0·64); high EPA+DHA (0·77 g,
n-3:n-6 ratio 0·28). Following the consumption of the con-
trol meal, ALA was mobilised from the gut as chylomicron
TAG, while conversion to longer-chain fatty acids
appeared to occur primarily in the liver and entered the cir-
culation esterified to phosphatidylcholine (PC) probably on
VLDL. The relative excursions of labelled n-3 fatty acids
in total plasma lipids over 21 d were ALA 84 %, EPA
7·9 % and docosapentaenoic acid (22:5n-3, DPA) 8·1 %.
There was no significant enrichment of DHA in any lipid
class. Incorporation of labelled ALA, EPA and DPA into
erythrocyte PC, followed a similar time-course to plasma
PC which suggests exchange of intact PC between lipopro-
teins and erythrocyte membranes. No significant effects of
meal n-3 fatty-acid content were observed upon the con-
version, or fractional oxidation, of [13C]ALA.
The second phase of studies examined the chronic effect
of altering the background diet n-3 fatty-acid content on
ALA conversion. The extent of conversion of ALA to
longer-chain fatty acids was determined over 48 h in a
sub-group of men (n 14) participating in the BBSRC-
LINK study, reported earlier. At baseline, the relative
cumulative excursions of labelled fatty acids in total
plasma were ALA 95·6 %, EPA 2·8 %, DPA 1·2 % and
DHA 0·04 %. The lower fractional enrichments in EPA
and DPA reflect the shorter time period over which
measurements were made. Increased dietary ALA (sub-
strate) did not drive an increase in ALA conversion, but
increasing dietary EPA+DHA (product) exerted a signifi-
cant product inhibition on EPA and DPA synthesis from
ALA. DHA synthesis was unaffected, suggesting that hepa-
tic DHA synthesis may be regulated independently from
EPA and DPA. There was no significant effect of n-3
fatty acid intake on the partitioning of [13C]ALA to oxi-
dation. In agreement with previous studies (Salem et al.
1999; Vermunt et al. 2000; Pawlosky et al. 2001), these
results indicate that conversion of ALA to EPA is limited
and to DHA, at best, marginal in well-nourished individ-
uals. It remains to be determined whether this process
can be up regulated during periods of increased demands
for n-3 long-chain PUFA.
Preliminary data from studies of ALA conversion in
women were also presented, suggesting that in 20–30-
year-olds ALA can be converted to DHA (9 %) to a greater
extent than in men. It was suggested that this may be hor-
monally up regulated, which raises the possibility that
DHA synthesis may increase in pregnancy and lactation
to meet the demands of the fetus and neonate for DHA.
Whether this observation has direct implications for risk
of cardiovascular disease is unclear.
Importance of a-linolenic acid as a source of long-chain
n-3 polyunsaturated fatty acid and its influence on risk
factors for cardiovascular disease
Dr Bruce Griffin and Professor Joe Millward presented
results from an FSA-funded study investigating the relative
effects of dietary ALA and fish oil on risk factors for
cardiovascular disease. In collaboration with Dr Steve
Wootton, this study also examined the effect of the
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background diet ALA:LA ratio on ALA conversion to its
long-chain derivatives using stable-isotope technology.
Sixty male subjects with an atherogenic lipoprotein pheno-
type (TAG .1·5 mmol/l, HDL ,1 mmol and a predomin-
ance of small, dense LDL) were recruited to a 12-week
dietary intervention trial. The subjects received one of
three diets: control (n-6:n-3 ratio 30); ALA (15 g/d, n-
6:n-3 ratio 0·46); EPA+DHA (3 g/d, n-6:n-3 ratio 5). The
diets were modified using sachets of oil, cooking oils, mar-
garines and capsules. The main findings from the study
were as follows.
The fish-oil diet increased erythrocyte EPA (2·5 to
6·6 %) and DHA (4·7 to 7·8 %), whereas the high ALA
diet increased ALA (0·3 to 1·2 %) and EPA (1·3 to
3·2 %), but not DHA (4·0 to 4·3 %). All diets decreased
serum cholesterol levels; serum TAG levels were
decreased by the fish-oil diet (20·59 mmol/l, P,0·001)
and the ALA diet (218 %, NS); though there were no sig-
nificant differences between diets on serum cholesterol,
TAG or in HDL- or LDL-cholesterol.
LDL subclasses showed a significant redistribution
towards larger, less dense particles only after fish oil,
with a fall in the relative abundance of small, dense LDL
(density 1·040–1·060 g/ml) (P,0·001). There was no
change in measures of haemostatic function including
factor VII, plasminogen activator inhibitor-1 and fibrino-
gen in response to any diet, or flow-mediated dilatation
after cuff-induced hyperaemia (endothelium-dependent)
or glyceryl trinitrate-induced vasodilatation (endothelium-
independent) in a subset of subjects on each diet.
In all subjects, conversion of [13C]ALA to [13C]EPA and
[13C]DPA isolated from both erythrocyte and plasma PC
fractions has been observed with very low (but significant)
levels of [13C]DHA formation. The 14 d 13C distribution
between ALA, EPA, DPA and DHA was 22, 53, 21 and
4 % respectively (mean values for erythrocyte and plasma
PC on both diets). The higher proportion of label in EPA
than in ALA (not theoretically possible for a unidirectional,
true precursor–product relationship) may partly reflect an
underestimation of the ALA labelling if peak labelling of
ALA occurred before the 24 h blood sample, or may indi-
cate differential exchange rates between plasma ALA and
EPA and intra-hepatic pools. The effect of background
diets on [13C]ALA conversion rates involved calculation
of standardised 13C values for EPA, DPA and DHA to cor-
rect for the varying precursor enrichment and this indicated
that mean values for [13C]EPA were higher after the flax
diet, suggestive of higher conversion, but not significantly
so given the marked between-subject variation. A much
larger group, and considerable expense, would be required
to demonstrate any significant difference.
The fish-oil diet produced predictably favourable
changes in blood lipids and lipoproteins, but had no
impact on the measures of haemostatic and endothelial
function that have been associated with the high risk dys-
lipidaemia in these subjects. The high-ALA diet produced
mild effects on serum lipids in relation to the fish-oil diet,
but produced no other measurable changes in our end-
points. The isotopic and membrane fatty-acid data indicate
that ALA was rapidly converted to EPA, and to DPA to
a significantly lesser degree, but is only very slowly
converted to DHA, at least as indicated by sampling of
blood-lipid pools. It may be that this low rate of DHA syn-
thesis is adequate to provide for usual metabolic demands
in these subjects. However it cannot increase DHA to the
level achieved by dietary DHA from fish oil thus prevent-
ing any fish-oil-like effects.
A double-blind controlled trial of dietary enrichment
with a-linolenic acid on vascular endothelial function in
human subjects
Dr Nicholas Pegge presented results from an FSA-funded
randomised controlled dietary intervention trial examining
the effect of supplementation with ALA in a healthy, free-
living population. The principal outcome measure was
assessment of arterial endothelial function. Secondary out-
come measures included measurement of blood lipids and
lipoproteins, homocysteine, vitamin status, full blood
counts, clotting factors, and measures of oxidative stress.
Two hundred healthy volunteers were supplemented for 6
months with one of four dietary interventions: capsules
of ALA (2 g/d); placebo capsules; bread milled with flax
seed sufficient to yield an equivalent amount of ALA to
capsule supplementation; placebo bread. The main findings
from the study were as follows.
Both forms of active supplementation increased the con-
centration of ALA and EPA, but not DHA, in plasma rela-
tive to placebo, but to a greater extent in those taking
active capsules than flax seed-enriched bread (62 v. 18 %;
P,0·001 and P¼0·01 respectively; P¼0·001 for the
difference).
Supplementation with pure encapsulated ALA decreased
arterial pulse wave velocity responsiveness to reactive
hyperaemia, indicative of a detrimental effect on endo-
thelial function (reduced from 5·0 to 2·4 % in the arm,
and from 8·2 to 4·9 % in the leg; P¼0·055 and
P,0·001). Neither active or placebo bread nor placebo
capsules had any significant effect on endothelial function.
ALA capsules decreased the plasma concentrations of
ApoA1 and ApoB (from 1·31 to 1·23, P¼0·007 and from
1·16 to 1·06, P¼0·049), but no intervention had any signifi-
cant effect on macronutrient intake, fasting lipid, homocys-
teine, vitamin A, C or E levels, or full blood counts.
This study suggests that there is no benefit to vascular
health from eating foods enriched with ALA, or taking sup-
plements of ALA, which may indeed be detrimental.
Effect of an increased intake of a-linolenic acid on
cardiovascular risk factors: the Mediterranean
Alpha-linolenic Enriched Groningen Dietary
Intervention study
The aim of the Mediterranean Alpha-linolenic Enriched
Groningen Dietary Intervention (MARGARIN) study was
to investigate the effects of an increased intake of ALA
on cardiovascular risk factors in a high-risk population
(Bemelmans et al. 2002). The study was double-blind
and participants were randomly assigned to receive either
an LA-rich margarine (58 % LA, 0·3 % ALA; n 157) or
an ALA-enriched margarine (46 % LA, 15 % ALA; n 109)
over 2 years. The subjects were hypercholesterolaemic
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(6–8 mmol/l) and had at least two other cardiovascular risk
factors (117 men, 149 women, 55 ^ 10 years). Among the
exclusion criteria were diabetes mellitus, and the use of
cholesterol-lowering drugs and acetylsalicylic acid. The
main findings from the study were as follows.
Among ALA-users, the contents of ALA and EPA in the
cholesteryl ester increased, and the content of arachidonic
acid, n-6:n-3 ratio and LA:ALA ratio decreased as com-
pared with the LA-users (P,0·01).
ALA-users had a higher total cholesterol:HDL-choles-
terol ratio (net difference þ0·34; 95 % CI 0·12, 0·56),
lower HDL-cholesterol level (20·05 mmol/l; 95 % CI
20·10, 0), higher TAG level (þ0·24 mmol/l; 95 % CI
0·02, 0·46), lower plasma fibrinogen level (20·18 g/l;
95 % CI 20·31, 20·04; after 1 year), and lower C-reactive
protein level (221 mg/l; 95 % CI 24·3, 0) than the LA-
users.
No significant differences existed in intima-media
thickening of the carotid and femoral arteries, auto-anti-
bodies against oxidised LDL, von Willebrand factor, and
soluble intercellular adhesion molecule.
In this study increased ALA intake had unfavourable
effects on the serum lipid profile, but had favourable
effects on markers for inflammation (C-reactive protein,
fibrinogen) when investigated against an LA-rich back-
ground diet. In the longer term, the anti-inflammatory
effects may outweigh the adverse effects on serum lipids,
with regard to cardiovascular events; however, due to the
short follow-up period and insufficient power of the MAR-
GARIN study it was impossible to investigate this. Future
research in primary prevention should focus on the events
as an outcome and on exploring a potential anti-inflamma-
tory mechanism.
Discussion
In adults, ALA supplementation causes an increase in the
blood and plasma levels of ALA, EPA and DPA but
hardly any, if at all, DHA. Increasing DHA in the diet
increases blood and plasma DHA levels. It was noted
that DHA precursor n-3 PUFA could be transported via
the plasma to tissues where subsequent conversion might
occur (for example, myocytes, astrocytes), and further iso-
topic studies need to investigate other compartments as
well as blood.
The studies presented as part of the present workshop
suggest little, if any, benefit of ALA, relative to LA, on
risk factors for cardiovascular disease; the effects observed
with fish-oil supplementation were not replicated by ALA
supplementation. No consistent beneficial effects of ALA
supplementation were observed on measures of endothelial
function, immune function, serum lipids or measures of
haemostatic function; whereas the long-chain derivatives
of ALA (EPA and DHA) have been demonstrated to
have beneficial effects. Although ALA supplementation
increases EPA there is no demonstrable benefit on the
risk factors investigated. There is a need, therefore, to
first prove the efficacy of ALA supplementation on cardio-
vascular disease, before further investigating effects on
cardiovascular risk factors.
The main cause of sudden death from acute heart attack
is ventricular fibrillation. Both clinical and animal studies
have suggested that n-3 PUFA have anti-arrhythmic effects
(Christensen et al. 1999, 2000; Leaf, 1999); indeed, the
most likely mechanism for the beneficial effect of EPA
and DHA on the re-occurrence of CHD is the stabilisation
of arrhythmias (Marchioli et al. 2002). It has been postu-
lated that this could be an underlying mechanism for the
beneficial effect of the Mediterranean ALA-rich diet in
the secondary prevention of CHD (de Lorgeril et al.
1994, 1999), either directly or via conversion to EPA
(Connor, 1999; Leaf, 1999). The present workshop, how-
ever, had reservations about the evidence suggesting a ben-
eficial effect of ALA on the secondary prevention of CHD,
and felt this still needed to be established.
The present workshop also highlighted the possibility of
feeding livestock ALA-rich oils to provide a means of
increasing the dietary intake in human consumers of EPA
and DHA. Issues such as the higher costs incurred to pro-
ducers would have to be addressed, as well as the need to
provide industry with clear scientific advice.
Recommendations
1. For further isotopic research, measures of the different
pools are needed (for example, heart), as well as
cheaper isotopes.
2. There is no reason to look further at existing CHD risk
factors in relation to ALA supplementation.
3. For a randomised clinical trial to investigate the effect
of ALA supplementation on the re-occurrence of CHD.
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University of Surrey; Dr Steve Wootton, University of
Southampton; Dr Nicholas Pegge, University of Wales
College of Medicine, Cardiff; Dr Wanda Bemelmans,
University of Groningen, The Netherlands; Dr William
Gilmore, Northern Ireland Centre for Diet and Health,
University of Ulster; Professor Christine Williams, Univer-
sity of Reading; Dr Anne Marie Minihane, University of
Reading; Professor Tom Sanders, King’s College,
London; Professor Joe Millward, University of Surrey;
Dr Philip Calder, University of Southampton; Dr Susan
Jebb, Human Nutrition Research, Cambridge; Dr Carmel
Moore, Human Nutrition Research, Cambridge; Professor
Rudolph Riemersma, University of Edinburgh; Professor
Klaus Wahle, Rowett Research Institute, Aberdeen; Dr
Mark Ramsey, University of Wales College of Medicine,
Cardiff; Dr Graham Burdge, University of Southampton;
Dr Tim Key, Cancer Research UK Epidemiology Unit,
Oxford; Dr Christina Goodacre, Department for Environ-
ment, Food and Rural Affairs; Dr Judy Buttriss, British
Nutrition Foundation; Ms Nilani Sritharan, Nutrition
Society; Professor Ian Givens, ADAS; Dr Kevin Shing-
field, ADAS, University of Reading; Ms Anne Heughan,
Unilever and Food and Drink Federation; Dr Elke
Trautwein, Unilever Research Vlaardingen; Dr Ray Rice,
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International Society for the Study of Fatty Acids and
Lipids; Dr Reto Muggli, Hoffmann-La Roche; Mr Rene´
Josse, Hoffmann-La Roche; Dr Lisa Jackson, FSA; Ms
Alette Weaver, FSA; Ms Rachel Elsom, FSA; Dr Peter
Sanderson, FSA.
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